WEZLANA 130 mg/26mL
ustekinumab-auub · INJECTION, SOLUTION · Nuvaila Limited
No Recall History
Plain English
WEZLANA is a injection, solution containing ustekinumab-auub at 130 mg/26mL, taken intravenous. Manufactured by Nuvaila Limited.
Key Facts
- Brand Name
- WEZLANA
- Generic Name
- ustekinumab-auub
- NDC Code (Product)
84612-066- Manufacturer
- Nuvaila Limited
- Strength
- 130 mg/26mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761331
- Drug Class
- Interleukin-12 Antagonist [EPC]; Interleukin-23 Antagonist [EPC]
- Marketing Start
- 01/01/2025
Recall History
No Recall HistoryFrequently Asked Questions
What is WEZLANA used for?
WEZLANA contains ustekinumab-auub. It is a injection, solution taken intravenous. Consult your doctor for specific uses.
Is WEZLANA a controlled substance?
WEZLANA is not classified as a controlled substance by the DEA.
What is the generic name for WEZLANA?
The generic name for WEZLANA is ustekinumab-auub. There are no other listed brand versions of ustekinumab-auub.
What is the NDC code for WEZLANA 130 mg/26mL?
The NDC (National Drug Code) for WEZLANA 130 mg/26mL is 84612-066, listed by Nuvaila Limited.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)